References
- Özkan G, Ulusoy S. 2013. Bleeding diathesis in hemodialysis patients. In: Suzuki H, editor. Hemodialysis. Rijeka, Croatia: InTech: pp 59–80
- Gangji A, Sohal A, Treleaven D, Crowther M. Bleeding in patients with renal insuffiency: A practical guide to clinical management. Thromb Res 2006;118:423–428
- Sohal A, Gangji A, Crowther M. Uremic bleeding: Patho-physiology and clinical risk factors. Thromb Res 2006;118:417–422
- Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Haemost 2004;30:579–589
- Bilgin A, Karadogan I, Artac M, Kizilors A, Bilgin R, Undar L. Hemodialysis shortens long in vitro closure times as measured by the PFA-100. Med Sci Monit 2007;13:141–145
- Rand M, Leung R, Packham M. Platelet assays. Transfus Apheresis Sci 2003;28:307–317
- Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. Lab Med 2002;126:133–146
- Wasiluk A. The expression of vWF receptor on newborn platelets. Med Sci Moint 2005;11:545–548
- Zupan I, Sabovic M, Salobir B, Ponikvar J, Cernelc P. Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis 2003;42:746–751
- Podda G, BucciarelIi P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: Comparison with the bleeding time. Thromb Haemost 2007;5:2393–2398
- Lancé MD, Henskens YM, Nelemans P, Theunissen MH, Oerle RV, Spronk HM, Marcus MA. Do blood collection methods influence whole-blood platelet function analysis? Platelets 2013;24:275–281
- European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. (Part 1). Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 2002;17:63–71
- Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152–163
- Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS). 2000. Document C28-2A. How to define and determine reference intervals in the clinical laboratory. Approved Guideline, 2nd ed. NCCLS, Wayne, PA
- Rabelink T, Zwaginga J, Koomans H, Sixma J. Thrombosis and hemostasis in renal disease. Kidney Int 1994;46:287–296
- Escolar G, Cases A, Vinas M, Pino M, Calls J, Isabel C, Ordinas A. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): Influence of hematocrit elevation. Haematologica 1999;84:614–619
- Kozek-Langevecker S, Masaki T, Mohammad H, Green W, Mohammed S, Cheung A. Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int 1999;56:299–305
- Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Perit Dial Int 2001;21:158–165
- Krawczyk W, Dmoszynska A, Marczewski K. The beginning of repeated hemodialysis treatment enhances some platelet functions in uremic patients. Nephron 1995;71:361–362
- Brophy D, Martin E, Carr S, Kirschbaum B, Carr M. The effect of uremia on contractile force, clot elastic modulus and bleeding time in hemodialysis patients. Thromb Res 2007;119:723–729
- Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006;19:317–322
- Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int 2012;82:147–157
- Sloand E, Sloand J. Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 1997;8:799–803